Cardiovascular diseases are the leading cause of death in the world. Platelets have a major role in cardiovascular events as they bind to the damaged endothelium activating and forming thrombi. Although some hydroquinone scaffold-containing compounds have known antiplatelet activities, currently there is a lack of evidence on the antiplatelet activity of hydroquinones carrying electron attractor groups. In this work, we evaluate the antiplatelet effect of a series of ortho-carbonyl hydroquinone derivatives on cytotoxicity and function of human platelets, using collagen and thrombin receptor activator peptide 6 (TRAP-6) as agonists. Our structure-activity relationship study shows that gem-diethyl/methyl substitutions and the addition/modifications of the third ring of ortho-carbonyl hydroquinone scaffold influence on the selective index (IC₅₀ TRAP-6/IC₅₀ Collagen) and the inhibitory capacity of platelet aggregation. Compounds 3 and 8 inhibit agonist-induced platelet aggregation in a non-competitive manner with IC₅₀ values of 1.77 ± 2.09 μM (collagen) and 11.88 ± 4.59 μM (TRAP-6), respectively and show no cytotoxicity. Both compounds do not affect intracellular calcium levels and mitochondrial bioenergetics. Consistently, they reduce the expression of P-selectin, activation of glycoprotein IIb/IIIa, and release of adenosine triphosphate and CD63 from platelet. Our findings may be used for further development of new drugs in platelet-related thrombosis diseases.

心血管疾病是世界上主要的死亡原因。血小板在心血管事件中起主要作用，因为它们与受损的内皮细胞结合并形成血栓。尽管某些含氢醌支架的化合物具有已知的抗血小板活性，但目前尚缺乏有关带有电子吸引子基团的氢醌的抗血小板活性的证据。在这项工作中，我们使用胶原蛋白和凝血酶受体激活肽6（TRAP-6）作为激动剂，评估了一系列邻羰基氢醌衍生物对人血小板的细胞毒性和功能的抗血小板作用。我们的结构-活性关系研究表明，宝石的-二乙基/甲基取代和C3的第三个环的添加/修饰邻羰基氢醌支架对选择性指数（IC ₅₀ TRAP-6 / IC ₅₀胶原蛋白）和血小板聚集抑制能力的影响。化合物3和8以非竞争性方式通过IC ₅₀抑制激动剂诱导的血小板凝集胶原蛋白值分别为1.77±2.09μM和11.88±4.59μM（TRAP-6），且无细胞毒性。两种化合物均不影响细胞内钙水平和线粒体生物能。一致地，它们降低了P-选择蛋白的表达，糖蛋白IIb / IIIa的激活以及血小板中三磷酸腺苷和CD63的释放。我们的发现可用于进一步开发与血小板相关的血栓形成疾病的新药。